Circulating CA 125 serum levels were measured in 60 patients with seve
ral hematological malignancies. Using 35 U/ml as cutoff level, elevate
d CA 125 concentrations were found in 3 of 18 patients with acute leuk
emia, 1 of 5 patients with chronic myelocytic leukemia, 2 of 9 patient
s with Hodgkin's lymphoma and in 14 of 28 patients with non-Hodgkin's
lymphoma. None of the healthy control group had CA 125 serum levels ab
ove 35 U/ml. In patients with malignant lymphoma, elevated CA 125 seru
m concentrations were associated with abdominal involvement (p < 0.01)
. 15 of 19 patients with abdominal tumor masses had CA 125 concentrati
ons above 35 U/ml, but only 1 of 18 patients with supradiaphragmatic i
nvolvement. Serial determinations of CA 125 were performed in 3 patien
ts with malignant lymphoma during chemotherapy. Disease regression was
associated with decreasing CA 125 serum levels. Thus, CA 125 may be a
useful indicator of abdominal involvement in patients with malignant
lymphoma. Moreover, serial CA 125 measurement may be of value in monit
oring response to chemotherapy in these patients.